Is Tirzepatide legal in European Union?

Mounjaro was authorised centrally on 15 September 2022. It is indicated for insufficiently controlled type 2 diabetes in adults, adolescents and children from 10 years, and for weight management in adults with obesity or with overweight plus a weight-related condition. It is prescription-only. Coverage depends on the member state: in Germany it is excluded from statutory health insurance when used for weight reduction (G-BA Annex II), in Italy it is reimbursed for type 2 diabetes but not for obesity, and France began reimbursing it for obesity on 15 June 2026 with strict criteria.